

1 **Bacterial Etiology of Urinary Tract Infections In patients treated at Kenyan Health**  
2 **Facilities And their resistance towards commonly used antibiotics**

3 **Author;**

4 Susan Kiiru<sup>1</sup>, John Maina<sup>1</sup>, Japhet Katana<sup>1</sup>, John Mwaniki<sup>1</sup>, Benon B Asimwe<sup>3</sup>, Stephen E  
5 Mshana<sup>4</sup>, Katherine Keenan<sup>6</sup>, Stephen H. Gillespie<sup>5</sup>, John Stelling<sup>7</sup>, John Kiiru<sup>1,2</sup>, Matthew T  
6 G Holden<sup>5</sup>, HATUA Consortium.

7 <sup>1</sup> *Centre for Microbiology Research, Kenya Medical Research Institute, PO Box 19464,*  
8 *00202, Nairobi, Kenya.*

9 <sup>2</sup> *National Public Health Laboratories, Ministry of Health, Kenya.*

10 <sup>3</sup> *School of Biomedical Sciences, Makerere University, Kampala, Uganda*

11 <sup>4</sup> *Department of Microbiology and Immunology, Catholic University of Health and Allied*  
12 *Sciences, Mwanza, Tanzania*

13 <sup>5</sup> *School of Medicine, University of St Andrews, St Andrews, UK.*

14 <sup>6</sup> *Geography and Sustainable Development, University of St Andrews, St Andrews, Fife, UK*

15 <sup>7</sup> *Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA*

16 *Corresponding author; [suzikoah@gmail.com](mailto:suzikoah@gmail.com), [SKiiru@kemri.go.ke](mailto:SKiiru@kemri.go.ke)*

17 **1.0 Abstract**

18 **Background**

19 Evidence-based empirical antibiotic prescribing requires knowledge of local antimicrobial  
20 resistance patterns. The spectrum of pathogens and their susceptibility strongly influences  
21 guidelines for empirical therapies for urinary tract infections (UTI) management.

22 **Objective**

23 This study aimed to determine the prevalence of UTI causative bacteria and their  
24 corresponding antibiotic resistance profiles in in three counties of Kenya. Such data could be  
25 used to determine the optimal empirical therapy.

26 **Methods**

27 In this cross-sectional study, urine samples were collected from patients who presented with  
28 symptoms suggestive of UTI in the following healthcare facilities; Kenyatta National  
29 Hospital, Kiambu Hospital, Mbagathi, Makueni, Nanyuki, Centre for Microbiology Research,  
30 and Mukuru Health Centres. Urine cultures were done on Cystine Lactose Electrolyte  
31 Deficient (CLED) to isolate UTI bacterial etiologies, while antibiotic sensitivity testing was  
32 done using the Kirby-Bauer disk diffusion using CLSI guidelines and interpretive criteria.

### 33 **Results**

34 A total of 1,027(54%) uropathogens were isolated from the urine samples of 1898  
35 participants. *Staphylococcus* spp. and *Escherichia coli* were the main uropathogens at 37.6%  
36 and 30.9 %, respectively. The percentage resistance to commonly used drugs for the  
37 treatment of UTI were as follows: trimethoprim (64%), sulfamethoxazole (57%), nalidixic  
38 acid(57%), ciprofloxacin (27%), amoxicillin-clavulanic acid (5%), and nitrofurantoin (9%)  
39 and cefixime ( 9%). Resistance rates to broad-spectrum antimicrobials, such as ceftazidime,  
40 gentamicin, and ceftriaxone, were 15%, 14%, and 11%, respectively. Additionally, the  
41 proportion of Multidrug-resistant (MDR) bacteria was 66%.

### 42 **Conclusion**

43 High resistance rates toward fluoroquinolones, sulfamethoxazole, and trimethoprim were  
44 reported. These antibiotics are commonly used drugs as they are inexpensive and readily  
45 available. Based on these findings, more robust standardised surveillance is needed to  
46 confirm the patterns observed while recognizing the potential impact of sampling biases on  
47 observed resistance rates.

48 **Keywords;** Uropathogens, UTI, antibiotic resistance.

### 49 **Background**

50 Urinary tract infections (UTIs) are among the community's most common infections  
51 [1] accounting for nearly 25% of all common infections[2]. Globally, UTI is more common  
52 among the aged, prepartum neonates, pregnant women, and hospitalized patients, especially  
53 those in Intensive Care Units (ICU) and those with indwelling catheters[3]. Usually,  
54 community-acquired UTIs are more prevalent than hospital-acquired UTIs[4]. Even though  
55 UTIs can be treated using antibiotics, previous widespread antibiotic usage without proper  
56 susceptibility testing has inevitably led to an increase in the proportion of UTI pathogens  
57 resistant to affordable and available antibiotics. Understanding local antimicrobial resistance  
58 patterns is a baseline step for evidence-based empirical antibiotic prescribing[5]. Continuous  
59 surveillance and monitoring of AMR trends are vital to informing clinical decisions during  
60 empirical management of UTIs in health facilities lacking laboratory capacity to perform  
61 culture and sensitivity tests. In order to administer an appropriate empirical therapy, it is  
62 critical to know the main uropathogens. [6].

68 It is estimated that ~50% of women will have at least one UTI episode in their  
69 lifetime, while 20-40% will have recurrent episodes [7]. Pregnant women are more  
70 susceptible to UTIs due to hormonal and physiologic changes predisposing them to

71 bacteriuria [8]. Up to 70% of pregnant women develop glycosuria, which encourages  
72 bacterial growth in the urine [9]. Antibiotic therapy for 70% of these infections usually  
73 begins before microbiological test results are known[10]. Furthermore, empirical therapy  
74 without a pretherapy urine culture is often used in women with acute uncomplicated cystitis.  
75 The rationale for this approach is based on the highly predictable spectrum of etiologic agents  
76 causing UTIs and their antimicrobial resistance patterns. However, antimicrobial resistance  
77 among uropathogens causing complicated and uncomplicated community-acquired UTIs is  
78 gradually increasing. Most significant has been the increasing resistance to  
79 trimethoprim/sulfamethoxazole (co-trimoxazole), commonly sold as Septrin™, the current  
80 drug of choice for treating acute uncomplicated cystitis in women [11]. In addition, SXT is  
81 frequently associated with concurrent resistance to other antibiotics classes, resulting in  
82 multidrug-resistant uropathogens [11].

83 In Kenya, the most common Gram-negative etiologic agents reported in UTI cases in  
84 order of decreasing prevalence are *Escherichia coli*, *Klebsiella*, *Enterobacter*, and *Proteus*.  
85 At the same time, *Staphylococcus* is the most common Gram-positive genus [12] followed by  
86 *Enterococcus*. Determining microorganisms and their antibiotic sensitivity patterns allows for  
87 good treatment outcomes, controls the increase of antimicrobial prescription, and helps  
88 prevent antimicrobial resistance, a public health problem worldwide. This paper establishes  
89 the common uropathogens from different healthcare facilities across Kenya and their  
90 corresponding susceptibility patterns.

## 91 **Methodology**

### 92 **Study Overview**

93 The finding reported in the present manuscript is a subset of a large Holistic Approach To  
94 Unravel Antibiotic-resistance (HATUA) consortium study in East Africa  
95 <https://pubmed.ncbi.nlm.nih.gov/34006022/>. This East African consortium included Kenya,

96 Uganda, and Tanzania. The study employed social science, microbiological, and molecular  
97 biology disciplines to unravel drivers of AMR holistically using UTI as the flag disease. In  
98 Kenya's HATUA chapter, the study was conducted in Nairobi, Makueni, and Nanyuki  
99 metropolis regions.

#### 100 **Study design and site**

101 A cross-sectional study design was employed to establish the common uropathogens  
102 recovered from purposively recruited 1898 patients with UTI-like symptoms. The  
103 participants were recruited from major public hospitals in Nairobi, Nanyuki, and  
104 Makueni counties in the former Nairobi, Central, and Eastern provinces, respectively, as  
105 shown in Fig 1. These counties were selected as there was limited information on  
106 uropathogens and their antibiotic resistance profiles. In each region, sampling was done from  
107 one level 5 hospital and in a maximum of 3 smaller hospitals or clinics (health centers, or  
108 Level 3 or 4), among participants who were living within the 70 km radius of the recruitment  
109 hospitals/clinics. The sampling regions included; Kenyatta National Hospital (a public,  
110 teaching, and national referral level 6 hospital), Mbagathi County level 5 Hospital (referral  
111 hospital in Nairobi region), Kiambu County level 5 Hospital (a referral hospital in Nairobi  
112 region), Nanyuki Teaching and Referral level 5 Hospital (referral hospital in the Central  
113 Region), and Makueni County Referral Level 5 Hospital (referral hospital in the Eastern).  
114 Most patients are referred from other facilities or come as self-referrals after treatment has  
115 been initiated at lower-level facilities. Mary Mother Mission Mukuru Healthcare (a health  
116 clinic in the second largest informal settlement in Nairobi), Ruiru Family Clinic (a private  
117 clinic in Nairobi county), KEMRI Centre for Microbiology Research Lab (a referral research  
118 facility that also houses the laboratory offering food handlers medical certification in Nairobi  
119 region).

120

121 **Fig1**; The location of study areas from where the recruitment occurred.

122

123 **Ethical Statement**

124 Before the start of the study, ethical approval was obtained from the Scientific Ethical  
125 Review Committee (SERU) of Kenya Medical Research Institute (No.  
126 KEMRI/SERU/CMR/P00112/3865). Additional ethical approval was obtained from National  
127 Commission for Science, Technology, and Innovation (NACOSTI) and the study recruitment  
128 healthcare facilities. Consent was sought before recruiting the participants for the study, and  
129 the names of the participants were not taken. The results approved by the project Principal  
130 Investigator were sent back to the medical doctor weekly, and presentations were done during  
131 the hospital's Continuing Medical Education meetings.

132 **Recruitment and laboratory procedures**

133 **Recruitment and sampling**

134 A medical doctor (resident in the hospital selected for study) identified patients who  
135 had symptoms suggestive of UTIs like burning pain after urinating, urgent need to urinate,  
136 pain or pressure in the lower abdomen, and cloudy, dark, bloody, or strange-smelling urine.  
137 The patients meeting the inclusion criteria were then referred to a study recruiting healthcare  
138 worker who was in a separate room within the hospital. For the inpatients, the doctor would  
139 request urine culture, and the nurses would assist in collecting the clean catch mid-stream  
140 urine aseptically, then send the urine to the hospital laboratory. The researcher in the  
141 laboratory would then request the nurse to help identify these inpatients and invite them to be  
142 recruited in the study, where they signed or thumb-signed the consent form. For children  
143 inpatients, the parent or guardian would give consent for them to participate in the study, then  
144 the child would thumb sign the assent form.

145 The researcher introduced the patient to the study and briefly explained the study  
146 objectives. Willing patients were then taken through the study informed consent document  
147 (ICD) in a language they could understand (English and/or Kiswahili), where they signed the

148 ICD, and for those who couldn't write, they thumb printed the ICD. Those who consented  
149 were given a study number that was filled in their questionnaire form. This study number was  
150 also written on the sample collection container. After consenting, the participant was  
151 requested to submit the urine samples.

152 A purposive sampling method was used to recruit patients that presented with UTI-  
153 like symptoms in the eight recruitment sites. Considering that there is overwhelming  
154 evidence that UTI diagnosis is complex and based mainly on dipsticks and microscopy that  
155 are frequently inaccurate[13], and considering that proper cultures for UTI are rarely  
156 performed in order to confirm UTI cases in many hospitals[8], therefore, the recruitment was  
157 standardised across countries, as per the protocol[14] briefly, to estimate precision, under a  
158 binomial model, the numbers required to obtain a 95% CI for the prevalence of 0.5 with  
159 width no greater than 0.1 would be a little under 400 (384). That model relies on there being  
160 no underlying population or sampling structure and so will lead to an underestimate of the  
161 true required numbers in our complex study. Our larger study size of 600 per country  
162 provided some robustness to our ability to estimate this parameter with the desired accuracy  
163 while allowing us to uncover some of the population structures that, if modelled correctly,  
164 will improve the precision in our estimate of prevalence. In level 2, 3, 4 and 5 hospitals in  
165 each study area, we recruited adult and child outpatients (minimum of 90% of the total  
166 sample) that a doctor identified as suffering with UTI-like symptoms (eg, burning/irritation  
167 during urination, dysuria and pyuria). In level 5 hospitals, we also recruited inpatients  
168 (maximum of 10% of the total). For non-pregnant child patients aged under 18 years, data  
169 was provided by an accompanying parent or guardian. Our sample is representative only of  
170 the population of clinic attendees rather than the general population and is likely to include a  
171 higher proportion of patients with treatment failures who are wealthier and patients living  
172 closer to clinics. However, clinic attendees are an important patient subset as these are the

173 individuals specifically for whom clinicians must make patient management and treatment  
174 decisions. The distribution of participants across the 8 recruitment sites depended on the  
175 proportion of patients visiting the hospital presenting with UTI-like symptoms and hence  
176 were not proportionally distributed.

### 177 **Urine collection procedure**

178 Clean-catch mid-stream urine was collected into 20 mL calibrated sterile screw-  
179 capped universal bottles. The adult participants were guided on how to collect the specimen  
180 by the fieldworker(s) aseptically. The fieldworker also assisted parents in collecting urine  
181 specimens from young children. Briefly, the parents had to take care the children did not  
182 touch the perineum with the collection tube; children older than two years who were able to  
183 follow instructions from their parents provided a mid-stream or clean catch sample of urine  
184 directly into sterile urine bottles under observation by one of the research staff. For those  
185 younger than two years or those who could not follow instructions, an in-and-out catheter  
186 was put in, and a sterile feeding tube size 5 or 6 was used to collect urine. A unique study  
187 identification number and barcode label was applied to the sample immediately after urine  
188 collection. To ensure urine was not contaminated by dipstick before culture, the collected  
189 urine was aliquoted in another sterile urine container labeled with the patient's unique  
190 number. The dipstick was then put in one of the aliquots for testing. The other portion of the  
191 urine aliquot was then kept in a cool box to be transported to the microbiology laboratory for  
192 further processing within 4 hours.

### 193 **Bacterial isolation and identification**

194 Urine samples were analyzed using dipstick strips, and urine colony count was  
195 determined in colony-forming units (CFUs) by culture as the gold standard. The patients were  
196 first screened by dipstick analysis in the hospital, using nitrites and leukocyte esterase



197 parameters to rule out the positive and negative tests. Both positive and negative urines by  
198 dipstick were then cultured on Cystine Lactose Electrolyte Deficient (CLED) agar and  
199 incubated at 37 °C overnight. Culturing both negative and positive urine was to detect  
200 possible UTI cases that may have been missed by dipstick test screening. A specimen was  
201 considered positive for Urinary Tract Infection (UTI) if the organism colony count was  
202 determined to be  $\geq 10^4$  CFU/mL with >5 pus cells per high-power field observed on  
203 microscopic examination of the urine as described by [15]. Additionally, bacterial  
204 identification was made using colony morphology, Gram staining, Triple Sugar Iron (TSI),  
205 citrate test, Lysine Indole Motility (LIM), Methyl Red and Voges Proskauer (MRVP), urease  
206 test, oxidase, catalase, and coagulase tests using commercially available NCTC 13420 to help  
207 in identification of *Acinetobacter baumannii*, NCTC 10975 to identify *Proteus mirabilis*,  
208 NCTC 12028 to identify *Morganella morganii*, NCTC 8900 to identify *Serratia marcescens*,  
209 *E.coli* ATCC 25922 and *S. aureus* ATCC 25923.

#### 210 **Antimicrobial Susceptibility testing**

211 Antimicrobial drug susceptibility testing was performed by the Kirby Bauer disk  
212 diffusion method on Mueller–Hinton agar following the M02 CLSI 2019 guidelines. The  
213 following Oxoid™ antimicrobial agents were used; ampicillin (AMP 10µg),  
214 amoxicillin/clavulanic acid (AMC 20/10µg), cefoxitin (FOX 30µg), cefotaxime (CTX 30µg),  
215 ceftazidime (CAZ 30µg), cefixime (CXM 30µg), ceftriaxone (CRO 30µg), ciprofloxacin  
216 (CIP 5µg), nalidixic acid (NAL 30µg), nitrofurantoin (NIT 300µg), trimethoprim (TMP 5µg),  
217 sulfamethoxazole (SMX 200-300 µg), gentamicin (GEN 10µg), chloramphenicol (CHL  
218 30µg), tetracycline (TCY 30µg), linezolid (LNZ 30µg), erythromycin (ERY 30µg),  
219 fosfomycin (FOS 30µg), amikacin (AMK 30µg), aztreonam (ATM 30µg). For each Gram-  
220 negative isolate, two plates with antibiotics were used, labeled as plates A and B. Plate A  
221 was used to screen for potential Extended Spectrum Beta-Lactamase (ESBL) production. The

222 arrangement of antibiotics was as follows, penicillins (AMP), 3<sup>rd</sup> generation cephalosporins  
223 (CXM, CRO, CAZ, CTX), cephamycin (FOX), monobactam (ATM), beta-lactamase  
224 inhibitor at the middle (AMC), and a 4<sup>th</sup>-generation cephalosporin (FEP). In plate B, CIP,  
225 NAL (targeting quinolones and fluoroquinolone resistance), GEN, AMK, and STR (targeting  
226 aminoglycoside resistance), CHL, TMP, SMX, FOS, NIT, and TCY were used since they are  
227 used in hospitals for treatments. Gram-positive isolates had two plates labeled plates A and B.  
228 Plate A had AMP, AMC, FOX, TMP, GEN, and NIT, and B had SMX, CIP, NAL, CHL,  
229 TCY, linezolid, erythromycin, and fosfomycin. *Escherichia coli* ATCC 25922 and  
230 *Staphylococcus aureus* ATCC 25923 were used for quality control of media quality and disc  
231 potency. The antibiograms generated were then used to cluster the isolates into various  
232 resistance profiles ranging from fully sensitive to multidrug-resistant. The strains exhibiting  
233 resistance to 3 or more classes or subclasses of antibiotics were scored as MDR[16].

## 234 **Results**

### 235 **Socio-demographic Characteristics and Prevalence of UTI.**

236 A total of 1898 patients who presented with UTI-like symptoms were recruited  
237 between May 2019 and August 2020. Among them, 1546 (81.5%) were females, while 352  
238 (18.5%) were males. A total of 67 (3.5%) were children ( $\leq 17$  years), and 1831 (96.5%) were  
239 adults. Of the adults, 1708 (93.3%) were outpatients, while 123 (6.7%) were inpatients.  
240 Twenty-two (32.8%) of the children were inpatients, while 45 (67.2%) were outpatients, as  
241 illustrated by Table 1 below. The average age of the study participants was  $30.7 \pm 12.1$  years,  
242 with the youngest being one year old and the oldest 102 years.

243 The overall pathogen isolation from patients with UTI-like symptoms was 1027(54.1  
244 %), with women having a higher isolation rate of 917 (59.3%) compared to men at  
245 110(31.3%). Bacteriuria was highest in the age group 25-30 years at 16.2% and the lowest  
246 (1.2%) in children under five years.

247 **Table.1 Demographic characteristics of the study participants**

248

Social demographic characteristics		Female	Male	Total
		N (%) (n = 1546)	N (%) (n = 352)	(n = 1898)
<b>Patient type</b>	Adult inpatient	81 (65.3)	43 (34.7)	124 (100)
	Adult outpatient	1429 (83.7)	278 (16.3)	1707 (100)
	Child inpatient	9 (40.9)	13 (61.9)	22 (100)
	Child outpatient	28 (62.2)	17 (37.8)	45 (100)
<b>Recruitment site</b>	CMR	17 (58.6)	12 (41.4)	29 (100)
	Kenya Ruiru Family clinic(KRF)	22 (81.5)	5 (18.5)	27 (100)
	KIAMBUR	182 (78.4)	50 (21.6)	232 (100)
	KNH	84 (67.2)	41 (32.8)	125 (100)
	MAKUENI	354 (92.7)	28 (7.3)	382 (100)
	MBAGATHI	112 (73.7)	40 (26.3)	152 (100)
	MMM	320 (82.7)	67 (17.3)	387 (100)
	NANYUKI	413 (85.5)	70 (14.5)	483 (100)
	<b>Study Location</b>	Central Kenya (Nanyuki)	414 (85.4)	71 (14.6)
Larger Nairobi Metropolis		778 (75.5)	253 (24.5)	1031 (100)
MAKUENI		354 (92.9)	27 (7.1)	381 (100)
<b>Age group</b>	< 5 years	10 (33.3)	20 (66.7)	30 (100)
	6-18 years	66 (81.5)	15 (18.5)	81 (100)
	19-24 years	425 (92.6)	34 (7.4)	459 (100)
	25-30 years	497 (84.5)	91 (15.5)	588 (100)
	31-35 years	249 (83.3)	50 (16.7)	299 (100)
	35-40 years	142 (78.5)	39 (21.5)	181 (100)
	41-45 years	60 (69.0)	27 (31.0)	87 (100)
	46-50 years	27 (60.0)	18 (40.0)	45 (100)
	51-55 years	21 (65.6)	11 (34.4)	32 (100)
	56-60 years	14 (53.8)	12 (46.2)	26 (100)
> 60 years	35 (50.7)	34 (49.3)	69 (100)	

249

250

251

252

253

254

255

256

257 **Bacterial isolates**

258                   Of all (1027/1898) UTI-positive patients, *Staphylococcus* spp. and *E. coli* were  
259 the main uropathogens isolated at 37.6% and 30.9%, respectively. Other uropathogens  
260 included *Enterococcus* spp 86 (8.4%), *Klebsiella* spp 91 (8.9%), *Proteus* spp 69( 6.7%),  
261 *Pseudomonas* spp. 8 (0.8%), *Acinetobacter* spp. 8 (0.8%). A total of 62(6%) organisms were  
262 regarded as miscellaneous in this study, as shown in Fig1. Gram-positive uropathogens were  
263 more prevalent at 524 (51%), followed by Gram-negative organisms at 490 (48%) and yeast  
264 at 10 (1%.)

265

266                   **Key; miscellaneous( *Serratia*, *Bacillus* and *Streptococcus* spp), E.coli- *Escherichia coli***

267                   **Fig 2:** Percentage proportion of Uropathogens recovered from 1027 positive cultures.

268

## 269 Antimicrobial Susceptibility Testing

270 The recovered uropathogens were subjected to antibiotic susceptibility testing.

271 However, yeast isolates were not tested, resulting in 1016 bacterial isolates for AST. Overall,

272 the percentage resistance to commonly used UTI drugs were as follows; trimethoprim (64%),

273 sulfamethoxazole (57%), nalidixic acid (57%), ciprofloxacin (27%), nitrofurantoin (9%),

274 cefixime (9%) and amoxicillin-clavulanic acid (5%). Resistance rates to broad-spectrum

275 antimicrobials, such as gentamicin, ceftriaxone, and ceftazidime, were at 14%, 9%, and 8%,

276 respectively. Cefixime, nitrofurantoin, and amoxicillin/clavulanic acid were the most

277 effective agents against these isolates, while trimethoprim, sulfamethoxazole, and nalidixic

278 acid were the most antibiotics with the highest resistance rates as seen in Fig 3.

279 *Staphylococcus* spp., the dominant uropathogen, showed the highest resistance towards

280 trimethoprim (76%), nalidixic acid (70%), sulfamethoxazole (67%), and ampicillin (64%).

281 Similarly, resistance towards ceftazidime was 38%, signifying the possibility of methicillin-

282 resistant *S. aureus* (MRSA) was 38%. Moreover, all isolated *Pseudomonas* spp (8) showed

283 resistance towards cefuroxime (100%) as well as high resistance towards ciprofloxacin

284 (39%), nalidixic acid (50%), nitrofurantoin (38%), sulfamethoxazole (38%) and trimethoprim

285 (38%). The proportion of multidrug-resistant (MDR) pathogens was 66%, with the most

286 common MDR phenotype observed being a combination of nalidixic acid, sulfamethoxazole,

287 and trimethoprim. Nalidixic acid is not included in the ECDC definition of MDR, but because

288 it is routinely used for UTI treatment, modifications were made to the definition of MDR.

289 The resistance towards nalidixic acid was high across all the recruitment sites, ranging from

290 52 to 71%, as Table 3 depicts. The resistance towards the mainstay treatments of UTI - beta-

291 lactams, quinolones, fluoroquinolones, and aminoglycosides, commonly abbreviated as

292 BFQA - was high in Kenyatta National Hospital, ranging from 31 to 43% and was lowest at

293 Ruiru Family Clinic ranging from 0 to 13%, as shown in the highlighted part of Table 3.

294

295

296 **Fig 3 antibiotics resistance profiles (%) of all the uropathogens recovered:** AMC- AMC-

297 Amoxicillin Clavulanic acid, AMP- Ampicillin, CXM-Cefixime, CAZ-Ceftazidime, CRO-Ceftriaxone, CTX-

298 Cefotaxime, FOX-Cefoxitin, ATM-Aztreonam, AMK-Amkacin, GEN-Gentamicin, NAL-Nalidixic Acid, CIP-

299 Ciprofloxacin, SMX-Sulfamethoxazole, TMP-Trimethoprim, FOS-Fosfomycin, NIT-Nitrofurantoin, LNZ-

300 Linezolid, CHL-Chloramphenicol, TCY-Tetracycline, Numbers in brackets are the n.

**Table 3: Antibiotic Resistance % across all recruitment sites.**

Study Site	AMP	AMC	CXM	CAZ	CRO	CTX	FOX	ATM	AMK	GEN	NAL	CIP	SMX	TMP	FOS	NIT	LNZ	CHL	TCY
CMR	41(17)	18(17)	0	18(17)	18(17)	24(17)	18(17)	33(6)	0	24(17)	71(17)	29(17)	41(17)	47(17)	0	6(20)	0	12(17)	29(35)
Kenyatta National Hospital	39(75)	32(75)	41(29)	37(75)	36(72)	37(75)	43(75)	63(35)	43(35)	37(75)	71(75)	37(75)	61(75)	64(75)	3(35)	19(77)	34(35)	20(75)	47(75)
Kiambu County hospital	23(126)	21(126)	37(41)	20(126)	21(125)	21(126)	25(126)	50(62)	10(62)	17(126)	61(126)	22(126)	51(127)	56(127)	0	12(125)	33(34)	10(130)	30(126)
Makueni Level 5	39(265)	13(265)	15(265)	15(265)	17(265)	18(265)	17(265)	47(135)	10(265)	11(265)	55(265)	20(265)	51(250)	69(250)	0	6(20)	19(6)	10(130)	43(265)
Mbagathi hospital	26(34)	26(34)	33(12)	18(34)	21(33)	26(34)	24(34)	53(15)	13(15)	16(34)	58(34)	21(34)	44(34)	68(34)	7(62)	16(70)	33(34)	12(135)	35(34)
Nanyuki county referral	37(325)	19(325)	18(255)	20(326)	23(326)	24(325)	17(321)	42(143)	10(325)	11(325)	52(325)	26(325)	59(325)	69(331)	3(35)	9(24)	26(30)	9(53)	39(325)
Ruiru family clinic	25(8)	13(8)	0	13(8)	13(8)	13(8)	13(8)	50(2)	0	13(8)	63(8)	13(8)	38(8)	38(8)	0	13(66)	0	13(66)	13(8)
MMM	48(159)	21(159)	0	21(160)	21(159)	23(159)	24(160)	41(94)	4(159)	13(159)	59(160)	14(160)	71(161)	57(160)	0	10(22)	15(24)	7(78)	38(27)

Key; AMC- Amoxicillin Clavulanic acid, AMP- Ampicillin, CXM-Cefixime, CAZ-Ceftazidime, CRO-Ceftriaxone, CTX-Cefotaxime, FOX-Cefoxitin, ATM-Aztreonam, AMK-Amkacin, GEN-Gentamicin, NAL-Nalidixic Acid, CIP-Ciprofloxacin, SMX-Sulfamethoxazole, TMP-Trimethoprim, FOS-Fosfomycin, NIT-Nitrofurantoin, LNZ-Linezolid, CHL-Chloramphenicol, TCY-Tetracycline, MMM-Mary Mother Mission Mukuru hospital, CMR-Centre for Microbiology Research.

## Discussion

In the current study, the prevalence of UTI was 54.1%, where of the those with UTI, Gram-positive bacteria were more prevalent at 51% than Gram-negative (48%) and yeast at (2%). This prevalence is higher than that from a study by Donkor *et al.* (2019) in Accra, Ghana, who reported a prevalence of 10.1% from patients who were clinically suspected of having a UTI [17]. In neighboring Uganda and Tanzania, a prevalence of 32.2% and 28%, respectively, have been reported, which considerably varies from the 54.1% recorded in the current study [18][9]. This implies that the community-acquired UTI burden varies across geographical locations and regions and is affected by varying study designs.

Furthermore, Onyango *et al.* reported a prevalence of 15.7% in a cross-sectional study conducted among pregnant women in a maternity hospital in Kenya [8]. In contrast, UTI prevalence in the above African studies significantly varies from the 11% overall prevalence in the United States where the target population was older women, both pregnant and not pregnant [19]. The variation in UTIs across regions may be attributed to variations in sanitation standards, urine collection procedure and sample, UTI history, patients' age, and sex composition across the populations. Moreover, the variation in prevalence may result from differences in patient and test inclusion criteria. For instance, the present study recruited patients who only presented with UTI-like symptoms. Therefore, their urine samples were cultured regardless of their nitrates and leukocyte esterases positivity rate. On the other hand, in the study by Odoki and colleagues, the recruited patients who presented with UTI-like symptoms had to cleanse the urethral area with castile soap towelette, reducing skin contamination chances [18]. This implies that there is need for more standardized testing for UTIs for better comparison and surveillance in future.

In the present study, Gram-positive uropathogens were more prevalent (51%) than Gram-negative uropathogens (48%). This contrasts with previous studies documenting a



lower prevalence of Gram-positive bacterial isolates at 21% and 12%, respectively[8] [20]. The predominance of Gram-positive bacteria could imply changing patterns of uropathogens. Other possibilities could be contamination from the skin during urine collection. Furthermore, the recovery of *Staphylococcus* spp. as the most dominant pathogen (34%) was different in other studies with *E. coli* as the main uropathogen. For example, in a study conducted in Kenya [20] the prevalence of *Staphylococcus* species was 21% and that of *E. coli* 38.5%, while another study conducted at Pumwani Hospital had a prevalence of 15.1% and *E. coli* at 44.5% [8]. Also, a study conducted in Pakistan resulted in a coagulase-negative staphylococci prevalence of 30.6% [21]. Additionally, *E. coli* was the second predominant uropathogen (26%), and the most prevalent Gram-negative bacteria, followed by *Klebsiella* spp. (9%) and *Proteus* spp. (7%) which is in agreement with a study carried out in Turkey that had *E. coli* as the most frequently isolated urinary pathogen (63.7%), followed by *K. pneumoniae* (18.7%) [22]. The recovery of *Pseudomonas* (0.7%) and *Acinetobacter* (1.3%), besides *E. coli* and *Klebsiella* spp., represents the most resistant bacterial populations to commonly used antibiotics, including carbapenems, and this poses a public health threat as there will be limited options to treat UTIs which are easily managed by antibiotics.

Antimicrobial resistance in these uropathogens may have had a significant implication in managing UTIs. For instance, the study shows a high prevalence of uropathogens with high resistance toward commonly UTI antibiotics, such as trimethoprim (64%), sulfamethoxazole (57%), and nalidixic acid (57%), which corroborates previous studies[8] [23]. Godman *et al.* (2018), shows that these are among the commonly prescribed antibiotics at most outpatient health facilities and are readily available over the counter at chemists and pharmacies[24]. The study found nitrofurantoin, amoxicillin-clavulanic acid, with the trade name Augmentin™, and cefepime as the better choice across all the study sites; this could be attributed to the fact that these drugs are not the first choice of treatment. The Gram-negative

bacteria exhibited more resistance to the commonly used UTI antibiotics than the Gram-positive bacteria, which was in agreement with a recently published study in Kenya that had the same resistant trend in uropathogens isolated from pregnant women[8]. Resistance to ciprofloxacin ranged from 12 to 67%. This trend must be closely watched since fluoroquinolones are superior to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole) for empirical therapy due to the relatively high prevalence of TMP/SMX resistance among uropathogens causing pyelonephritis [25][26]. Additionally, *Pseudomonas* spp. and *Acinetobacter* spp. revealed resistance towards nitrofurantoin at 38% and 25%, respectively. This is worrying as nitrofurantoin appears to be an ideal alternative to co-trimoxazole and fluoroquinolones for empirical treatment of uncomplicated UTIs, especially given the current prevalence of antibiotic resistance among community uropathogens [27].

Additionally, variation in resistance across recruitment sites was significant. This could be attributed to self-medication practices where the community members buy the currently available drugs from the chemists around[28]. Self-medicating individuals also predominantly use the same affordable antibiotics[28]. However, different areas have a diverse supply of antibiotics hence the variation in resistance[29]. This suggests limited treatment options, making UTIs challenging to treat and posing an apparent threat to public health. Elsewhere, the high rate of resistance of uropathogens to commonly used antibiotics and the emergence of *S. aureus* as a significant causative agent could indicate a problem at the community or facility level due to wrong prescription, over-prescription, or poor adherence. This highlights the need for continuous local surveillance of susceptibility patterns of uropathogens so that a guide for empirical antibiotic prescription can be updated.

## **Conclusion**

The study documents a high prevalence of UTIs and Gram-positive bacteria as the most dominant uropathogens implying changes in uropathogens patterns. The possible

consequence of this could be a wrong antibiotics prescription since Gram-negative bacteria have previously been prevalent. Furthermore, high resistance rates towards quinolones, sulfamethoxazole, and trimethoprim were reported, which are the commonly used drugs as they are cheap to buy and readily available. These findings, therefore, indicate the need to for more robust standardised surveillance is needed to confirm the patterns observed. The study also highlights the need for the identification of the causative agent of UTI, even though not all hospitals have the capacity to carry out the cultures. Therefore, annual surveillance of the circulating UTI causative agents should be adopted to update the national guidelines for antibiotics empirical therapy accordingly.

### **Study limitations**

This study recruited patients seeking treatment for UTI-like symptoms and therefore prevalence reported in the present study may not reflect the actual prevalence in the community. This assumption is further reinforced by the fact a substantial number of patients in poor resource settings frequently opt for self-treatment and only visit hospital for severe UTI cases or when symptoms have persisted[30]. Regardless, our study provides a good glimpse into the UTI burden in Kenya, considering this is the largest UTI study in Kenya by sampling sites and sample size.

### **Funding information**

The Holistic Approach to Unravel Antibacterial Resistance in East Africa (HATUA) is a 3-year Global Context Consortia Award (MR/S004785/1) funded by the National Institute for Health Research, Medical Research Council and the Department of Health and Social Care. The award is also part of the EDCTP2 program supported by the European Union. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript

### **Conflict of interests**

The authors declare that there are no conflicts of interest

### **Authors contribution**

Susan Kiiru led the antibiotic susceptibility testing team and has drafted this manuscript. In addition, John Maina and Japhet Katana were involved in the crucial components of the study's methodology formulation and actualization. Dr. John Mwaniki was involved in the conceptualization and actualization. of the study, and reviewed and edited the initial drafts of this paper. Katherine Keenan, Stephen H. Gillespie, and John Stelling contributed to the study design and protocol writing and reviewed the manuscript. Dr. John Kiiru is part of the team that conceptualized the study, and the HATUA Kenyan Chapter lead and provided overall supervision of the study. Prof. Matthew Holden is the HATUA principal investigator and the one who received the funding.

### **Acknowledgments**

We are indebted to the Medical Research Council UK for providing financial support to the study. We also acknowledge the HATUA study collaborators, St. Andrews University, Scotland, Makerere University, Uganda, and the Catholic University of Health and Allied Sciences in Mwanza, Tanzania. We also appreciate the health facilities that allowed us to conduct our study on their premises. Finally, our heart goes to the participants, whom the study couldn't have been possible without them.

## References

- [1] Lee DS, Lee S-J, Choe H-S, Giacobbe DR. Community-Acquired Urinary Tract Infection by *Escherichia coli* in the Era of Antibiotic Resistance 2018. <https://doi.org/10.1155/2018/7656752>.
- [2] Al-Badr A, Al-Shaikh G. Recurrent Urinary Tract Infections Management in Women: A review. *Sultan Qaboos Univ Med J* 2013;13:359. <https://doi.org/10.12816/0003256>.
- [3] Öztürk R, Murt A. Epidemiology of urological infections: a global burden. *World J Urol* 2020;38:2669–79. <https://doi.org/10.1007/S00345-019-03071-4/METRICS>.
- [4] Islam MA, Islam MR, Khan R, Amin MB, Rahman M, Hossain MI, et al. Prevalence, etiology and antibiotic resistance patterns of community-acquired urinary tract infections in Dhaka, Bangladesh. *PLoS One* 2022;17:e0274423. <https://doi.org/10.1371/JOURNAL.PONE.0274423>.
- [5] Walters EM, D’Auria J, Jackson C, Walsh-Kelly C, Park D, Willis ZI. An Ambulatory Antimicrobial Stewardship Initiative to Improve Diagnosis and Treatment of Urinary Tract Infections in Children. *The Joint Commission Journal on Quality and Patient Safety* 2019;45:829–37. <https://doi.org/10.1016/J.JCJQ.2019.08.004>.
- [6] Emiru T, Beyene G, Tsegaye W, Melaku S. Associated risk factors of urinary tract infection among pregnant women at Felege Hiwot Referral Hospital, Bahir Dar, North West Ethiopia. *BMC Res Notes* 2013;6. <https://doi.org/10.1186/1756-0500-6-292>.
- [7] Dash M, Padhi S, Mohanty I, Panda P, Parida B. Antimicrobial resistance in pathogens causing urinary tract infections in a rural community of Odisha, India. *J Family Community Med* 2013;20:20–6. <https://doi.org/10.4103/2230-8229.108180>.
- [8] Onyango HA, Ngugi C, Maina J, Kiiru J. Urinary Tract Infection among Pregnant Women at Pumwani Maternity Hospital, Nairobi, Kenya: Bacterial Etiologic Agents, Antimicrobial Susceptibility Profiles and Associated Risk Factors. *Adv Microbiol* 2018;08:175–87. <https://doi.org/10.4236/aim.2018.83012>.
- [9] Kaduma J, Seni J, Chuma C, Kirita R, Mujuni F, Mushi MF, et al. Urinary Tract Infections and Preeclampsia among Pregnant Women Attending Two Hospitals in Mwanza City, Tanzania: A 1:2 Matched Case-Control Study 2019. <https://doi.org/10.1155/2019/3937812>.
- [10] Onyango HA, Ngugi C, Maina J, Kiiru J. Urinary Tract Infection among Pregnant Women at Pumwani Maternity Hospital, Nairobi, Kenya: Bacterial Etiologic Agents, Antimicrobial Susceptibility Profiles and Associated Risk Factors. *Adv Microbiol* 2018;08:175–87. <https://doi.org/10.4236/AIM.2018.83012>.
- [11] Shiralizadeh S, Taghizadeh S, Asgharzadeh M, Shokouhi B, Gholizadeh P, Rahbar M, et al. Urinary tract infections: raising problem in developing countries. *Undefined* 2018;29:159–65. <https://doi.org/10.1097/MRM.0000000000000144>.

- [12] Masika WG, Prudhomme O'meara W, Holland TL, Armstrong J. Contribution of urinary tract infection to the burden of febrile illnesses in young children in rural Kenya 2017. <https://doi.org/10.1371/journal.pone.0174199>.
- [13] Chambliss AB, Van TT. Revisiting approaches to and considerations for urinalysis and urine culture reflexive testing. <https://doi.org/10.1080/10408363.2021.1988048>.
- [14] Asimwe BB, Kiiru J, Mshana SE, Neema S, Keenan K, Kesby M, et al. Protocol for an interdisciplinary cross-sectional study investigating the social, biological and community-level drivers of antimicrobial resistance (AMR): Holistic Approach to Unravel Antibacterial Resistance in East Africa (HATUA). *BMJ Open* 2021;11:e041418. <https://doi.org/10.1136/BMJOPEN-2020-041418>.
- [15] Bono MJ, Leslie SW, Reygaert WC. Urinary Tract Infection. *StatPearls* 2022.
- [16] Sweeney MT, Lubbers B v, Schwarz S, Watts JL. Applying definitions for multidrug resistance, extensive drug resistance and pandrug resistance to clinically significant livestock and companion animal bacterial pathogens n.d. <https://doi.org/10.1093/jac/dky043>.
- [17] Donkor ES, Horlortu PZ, Dayie NT, Obeng-Nkrumah N, Labi A-K. Community acquired urinary tract infections among adults in Accra, Ghana 2019. <https://doi.org/10.2147/IDR.S204880>.
- [18] Odoki M, Aliero AA, Tibyangye J, Maniga JN, Wampande E, Kato CD, et al. Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda 2019. <https://doi.org/10.1155/2019/4246780>.
- [19] Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. *Am J Obstet Gynecol* 2018;219:40–51. <https://doi.org/10.1016/J.AJOG.2017.12.231>.
- [20] Wanja F, Ngugi C, Omwenga E, Maina J, Kiiru J, Wanja F, et al. Urinary Tract Infection among Adults Seeking Medicare at Kiambu Level 5 Hospital, Kenya: Prevalence, Diversity, Antimicrobial Susceptibility Profiles and Possible Risk Factors. *Adv Microbiol* 2021;11:360–83. <https://doi.org/10.4236/AIM.2021.118028>.
- [21] Hussain T, Moqadasi M, Malik S, Salman Zahid A, Nazary K, Khosa SM, et al. Medicine, Army Medical College Rawalpindi, Rawalpindi, PAK 4. Internal Medicine, Allama Iqbal Memorial Teaching Hospital, Lahore, PAK 5. Internal Medicine, Kabul University of Medical Science, Kabul, AFG 6. Pathologist, IND 11. Neurological Surgery, Ali Abad Teaching Hospital. *Jinnah Medical* 2021. <https://doi.org/10.7759/cureus.17527>.
- [22] Erdem I, Kara Ali R, Ardic E, Elbasan Omar S, Mutlu R, Topkaya A. Community-acquired lower urinary tract infections: Etiology, antimicrobial resistance, and treatment results in female patients. *J Glob Infect Dis* 2018;10:129–32. [https://doi.org/10.4103/jgid.jgid\\_86\\_17](https://doi.org/10.4103/jgid.jgid_86_17).
- [23] Haque R, Akter ML, Salam MA. Prevalence and susceptibility of uropathogens: A recent report from a teaching hospital in Bangladesh. *BMC Res Notes* 2015;8:1–5. <https://doi.org/10.1186/S13104-015-1408-1/TABLES/3>.

- [24] Mukokinya MA, Opanga S, Oluka M, Godman B. Dispensing of Antimicrobials in Kenya: A Cross-sectional Pilot Study and Its Implications. *J Res Pharm Pract* 2018;7:77–82. [https://doi.org/10.4103/JRPP.JRPP\\_17\\_88](https://doi.org/10.4103/JRPP.JRPP_17_88).
- [25] *Escherichia coli* from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams - PubMed n.d. <https://pubmed.ncbi.nlm.nih.gov/19734602/> (accessed October 21, 2022).
- [26] Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. *Int J Antimicrob Agents* 2003;22:65–72. [https://doi.org/10.1016/S0924-8579\(03\)00238-3](https://doi.org/10.1016/S0924-8579(03)00238-3).
- [27] Mckinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. *Mayo Clin Proc* 2011;86:480–8. <https://doi.org/10.4065/MCP.2010.0800>.
- [28] Green DL, Keenan K, Fredricks KJ, Huque SI, Mushi MF, Kansiime C, et al. The role of multidimensional poverty in antibiotic misuse: a mixed-methods study of self-medication and non-adherence in Kenya, Tanzania, and Uganda. *Lancet Glob Health* 2023;11:e59–68. [https://doi.org/10.1016/S2214-109X\(22\)00423-5](https://doi.org/10.1016/S2214-109X(22)00423-5).
- [29] Zanichelli V, Monnier AA, Gyssens IC, Adriaenssens N, Versporten A, Pulcini C, et al. Variation in antibiotic use among and within different settings: a systematic review. *Journal of Antimicrobial Chemotherapy* 2018;73:vi17–29. <https://doi.org/10.1093/JAC/DKY115>.
- [30] Charles Kiragu Ngigi B. SELF MEDICATION WITH ANTIBIOTICS PRIOR TO SEEKING TREATMENT AMONG ADULT PATIENTS ATTENDING OUTPATIENT DEPARTMENT AT GATUNDU SUB-COUNTY HOSPITAL, KIAMBU COUNTY, KENYA 2016.







